Breaking news on endocrinology
Breast Cancer Response To Estrogen Regulated By Previously Unseen Switch published
Fri, 09 May 2008 04:00:00 PDT
A tiny modification called methylation on estrogen receptors prolongs the life of these growth-driving molecules in breast cancer cells, according to research by scientists at Emory University's Winship Cancer Institute.The results are published in the May 9, 2008 issue of the journal Molecular Cell.Most breast cancers contain estrogen receptors, which enable them to grow in the presence of the hormone estrogen.
Naturally Occurring Protein May Be Effective In Limiting Hart Attack Injury And Restoring Function published
Fri, 09 May 2008 00:00:00 PDT
Medical College of Wisconsin researchers in Milwaukee have shown for the first time that thrombopoietin (TPO), a naturally occurring protein being developed as a pharmaceutical to increase platelet count in cancer patients during chemotherapy, can also protect the heart against injury during a heart attack.The study, led by John E.
Preliminary Results From Phase 2 Genzyme Study Highlight Potential Of Novel Oral Compound For Gaucher Disease published
Thu, 08 May 2008 00:00:00 PDT
Genzyme Corp. (Nasdaq: GENZ) reported that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compound produced a meaningful impact on key clinical manifestations of Gaucher disease. The results highlight the potential of this compound to become an innovative treatment option for Gaucher disease.
Signs Of Aging Might Instead Be A Treatable Thyroid Disorder published
Thu, 08 May 2008 00:00:00 PDT
It's wrong to assume that fatigue or memory loss is an inevitable sign of aging. They also are common symptoms of an underactive thyroid -- a condition that generally responds to treatment, according to the May issue of Mayo Clinic Health Letter.The thyroid gland, in the neck just below the Adam's apple, plays a significant role in overall health.
No Need To Endure Excessive, Embarrassing Sweating published
Thu, 08 May 2008 00:00:00 PDT
When shaking someone's hand becomes a self-conscious ordeal because of excessive sweating, talk to a care provider. The May issue of Mayo Clinic Health Letter outlines treatment options to help minimize excessive sweating.Called focal hyperhidrosis, this condition most commonly involves excessive daytime sweating of the palms, soles and underarms. It can make typical work and social activities hard to endure.
Food Made To Appear More Delicious By Gut Hormone published
Wed, 07 May 2008 03:00:00 PDT
A gut hormone that causes people to eat more does so by making food appear more desirable, suggests a new report in the May issue of Cell Metabolism, a publication of Cell Press. In a brain imaging study of individuals, the researchers found that reward centers respond more strongly to pictures of food in subjects who had received an infusion of the hormone known as ghrelin.
Divigel(R) (estradiol Gel) 0.1 Percent Offers Lowest Approved Dose Of Estradiol For Treatment Of Moderate To Severe Hot Flashes published
Tue, 06 May 2008 00:00:00 PDT
Medical specialists from around the country will gather this week to discuss the latest research in obstetrics and gynecology, and menopause and estrogen therapy will be among the information presented. "Estrogen therapy continues to be the gold standard for the management of hot flashes, the most common physical sign of menopause," said Dr.
Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression Of Hormones In Children With Premature Onset Puberty published
Tue, 06 May 2008 00:00:00 PDT
Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced positive results of the ongoing Phase III extension study of SUPPRELIN(R) LA (histrelin acetate), the only once-yearly subcutaneous implant for the treatment of central precocious puberty or early onset puberty, at the Lawson Wilkins Pediatric Endocrine Society (LWPES) Annual Meeting.
Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra(TM) Clinical Trial In Neuroblastoma Patients published
Mon, 05 May 2008 01:00:00 PDT
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that it has initiated a Phase 2a clinical trial of Azedra (Ultratrace™ iobenguane I-131 or Ultratrace MIBG) for the treatment of children with high-risk neuroblastoma, a neuroendocrine cancer that primarily affects children. Azedra is already being evaluated in an ongoing dose-ranging clinical trial for pheochromocytoma in adults.
New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin Like Growth Factor Receptor published
Fri, 02 May 2008 00:00:00 PDT
Therapies under development to treat prostate cancer by inhibiting the ability of insulin-like growth factor (IGF-1) to activate its target receptor could have unexpected results, especially if a major tumor suppressor gene -- p53 -- is already compromised, according to new research by investigators at Fred Hutchinson Cancer Research Center.
Ingredient In The Pill Could Prevent Brain Damage After Head Injury published
Thu, 01 May 2008 04:00:00 PDT
A common component of the contraceptive pill (progesterone) could improve the neurologic outcome for patients with severe head injuries, according to a study published in BioMed Central's open access journal Critical Care.Traumatic brain injury (TBI), such as that caused by traffic accidents, falls and sporting injuries, is a major cause of death and disability.
Insulin Resistance And Atherosclerosis: The "Missing Link" published
Wed, 30 Apr 2008 00:00:00 PDT
New research will highlight the "missing link" between the insulin resistance (metabolic) syndrome and cardiovascular disease at the American Association of Clinical Endocrinologists (AACE) 17th Annual Meeting & Clinical Congress, on Thursday, May 15, 2008, at the Walt Disney World Dolphin Resort in Orlando."Insulin resistant patients face a constellation of cardiovascular risk factors without diabetes ever being present," AACE Member and the session's speaker Ralph A.
Discovery Of Stem Cells In The Pituitary Gland Of Mice Suggests A Means Of Adapting To Stress And Life Changes published
Tue, 29 Apr 2008 02:00:00 PDT
A team of researchers led by scientists at Cold Spring Harbor Laboratory have for the first time identified stem cells that allow the pituitary glands of mice to grow even after birth. They found that, in contrast to most adult stem cells, these cells are distinct from those that fuel the initial growth of this important organ.
Understanding How Mosquitoes Weather The Winter Has Potential To Enable Manipulation of Mosquito Populations published
Sun, 27 Apr 2008 06:00:00 PDT
Two genes that help insulin regulate mosquitoes' growth have been identified as key contributors to how the insects enter a dormant state to survive winter's cold.The research finding broadens the understanding of the mosquito life cycle and appears to shed some light on how other insects and invertebrate species weather the winter months.The shorter days of autumn trigger certain species of mosquitoes into
Women's Biological Clock Revealed: Hormone May Predict Age At Menopause published
Sun, 27 Apr 2008 00:00:00 PDT
Age at menopause may now be predicted more realistically according to a new study accepted for publication in the Journal of Clinical Endocrinology & Metabolism (JCEM). The study revealed that anti Mullerian hormone (AMH) levels are related to the onset of menopause and are able to specify a woman's reproductive age more accurately than chronological age alone.The levels of AMH in the blood reflect the number of small follicles present in a woman's ovaries.
FDA Approves New Once-a-Month Dose Of Actonel For Postmenopausal Osteoporosis published
Fri, 25 Apr 2008 00:00:00 PDT
The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel(R) (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis. The FDA approval of the once-a-month dose is based on a study comparing Actonel 150 mg once monthly to Actonel 5 mg daily.
Simultaneous Testing For Thyroid Hormones published
Tue, 22 Apr 2008 01:00:00 PDT
Randox Laboratories produces Thyroid Array biochips to simultaneously test for three thyroid hormones in a single sample. Thyroid-stimulating hormone (TSH) is released by the pituitary gland in the brain. Thyroxine (FT4 or TT4) and tri-iodothyronine (FT3 or TT3) are hormones produced by the thyroid gland. TSH is performed as the initial screening test and all three hormones are essential in the diagnosis of thyroid disease.
Health, Bioidentical Hormones And Mother's Day News published
Mon, 21 Apr 2008 14:00:00 PDT
What do bioidentical hormones and Mother's Day have in common? The official kick-off for the ninth annual National Women's Health Week (May 11-17). The U.S. Department of Health and Human Services' Office on Women's Health, is asking "women across the country to get healthy by taking action." This includes checking hormonal balance and symptoms associated with menopause, adrenal fatigue and perimenopause.
Twice As Many Short Boys As Girls In The US And Asia Treated With Growth Hormone published
Fri, 18 Apr 2008 04:00:00 PDT
Boys are twice as likely as girls in the U.S. and Asia (mostly Japan) to receive recombinant human growth hormone (rhGH) for growth hormone deficiency, illnesses that affect height, and short stature of a non-medical nature. A smaller gender difference exists in Europe, Australia and New Zealand, but in the rest of the world short boys and girls are treated at the same rate. This indicates a likely cultural bias for male height in some countries.
Belly Fat May Be Stimulating Appetite published
Thu, 17 Apr 2008 04:00:00 PDT
The extra fat we carry around our middle could be making us hungrier, so we eat more, which in turn leads to even more belly fat. Dr. Kaiping Yang and his colleagues at the Lawson Health Research Institute affiliated with The University of Western Ontario found abdominal fat tissue can reproduce a hormone that stimulates fat cell production. The researchers hope this discovery will change in the way we think about and treat abdominal obesity.
A Mixed Set Of Results From 5-Alpha-Reductase Inhibitors And Reduced Prostate Cancer Risk published
Wed, 16 Apr 2008 05:00:00 PDT
Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5-9% to around 4-6% during up to 7 years of treatment, according to a new Cochrane Review. However, those who are diagnosed with prostate cancer may be at a slightly increased risk of having a more dangerous (high grade) tumour.
Medarex Reports Interim Data From Ongoing Ipilimumab Combination Phase 1 Studies In Prostate Cancer At American Association For Cancer Research published
Wed, 16 Apr 2008 00:00:00 PDT
Medarex, Inc. (Nasdaq: MEDX) announced interim results from two ongoing Phase 1 trials in hormone refractory prostate cancer (HRPC) demonstrating dose-dependent T-cell activation and clinical activity of ipilimumab, an investigational anti-CTLA-4 antibody.
Genmab A/S - Company Announcement: Novel Insights Into HuMax-EGFr Mechanisms Of Action Published In PNAS published
Wed, 16 Apr 2008 00:00:00 PDT
Summary: Genmab has announced that HuMax-EGFr (zalutumumab) inhibits epidermal growth factor receptor signaling by locking epidermal growth factor receptor (EGFr) molecules into a very compact, inactive conformation. The flexibility of the EGFr is central to its role in signaling, and binding of HuMax-EGFr (zalutumumab) results in effective inhibition of cancer cell growth.
Research Provides Insight Into Irrational Decision Making During Crashes And Bubbles published
Tue, 15 Apr 2008 05:00:00 PDT
When City traders have high morning testosterone levels they make more than average profits for the rest of that day, researchers at the University of Cambridge have discovered.The scientists hypothesize that this may be because testosterone has been found to increase confidence and appetite for risk - qualities that would augment the performance of any trader who had a positive expected return.
Bionovo Identifies And Describes ER-beta Selective Compounds For The Treatment Of Vaginal Dryness published
Tue, 15 Apr 2008 00:00:00 PDT
Bionovo, Inc. (Nasdaq: BNVI) will present seminal information on a new drug candidate for the treatment of vaginal dryness at the 7th Annual Oxford International Conference on the Science of Botanicals & American Society of Pharmacognosy 4th Interim Meeting, April 12-16, 2008. Scott Baggett, Ph.D.
)
|
|
